Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
Journal of Neurology
|
November 1, 1988
Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease
P Foley, H F Bradford, M Docherty, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|
November 1, 1989
Antibodies in serum of patients with Alzheimer's disease cause immunolysis of cholinergic nerve terminals from the rat cerebral cortex
H F Bradford, P Foley, M Docherty, et al.
Clinical and Experimental Immunology
|
December 1, 1978
Serial studies on circulating immune complexes in post-streptococcal sequelae
I van de Rijn, H Fillit, W E Brandeis, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 1, 2024
Alzheimer's Disease Linkage to Real-World Evidence (AD-LINE) Study: Linking Claims Data to Phase 3 GRADUATE Study of Gantenerumab
H Fillit, S Seleri Assunção, T Majda, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 16, 2022
Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment
C G Lyketsos, S B Roberts, E K Swift, et al.
The Journal of Prevention of Alzheimer'S Disease
|
April 19, 2025
Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force
D Angioni, L Middleton, R Bateman, et al.
The Journal of Prevention of Alzheimer'S Disease
|
September 29, 2021
Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force
J Kaye, P Aisen, R Amariglio, et al.
The Journal of Prevention of Alzheimer'S Disease
|
May 8, 2019
Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force
S Gauthier, J Alam, H Fillit, et al.
The Journal of Prevention of Alzheimer'S Disease
|
December 21, 2018
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
D A Messner, P Rabins, A C Downing, et al.
The Journal of Prevention of Alzheimer'S Disease
|
June 25, 2023
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
D Angioni, O Hansson, R J Bateman, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
Journal of Neurology
|
November 1, 1988
Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease
P Foley, H F Bradford, M Docherty, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|
November 1, 1989
Antibodies in serum of patients with Alzheimer's disease cause immunolysis of cholinergic nerve terminals from the rat cerebral cortex
H F Bradford, P Foley, M Docherty, et al.
Clinical and Experimental Immunology
|
December 1, 1978
Serial studies on circulating immune complexes in post-streptococcal sequelae
I van de Rijn, H Fillit, W E Brandeis, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 1, 2024
Alzheimer's Disease Linkage to Real-World Evidence (AD-LINE) Study: Linking Claims Data to Phase 3 GRADUATE Study of Gantenerumab
H Fillit, S Seleri Assunção, T Majda, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 16, 2022
Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment
C G Lyketsos, S B Roberts, E K Swift, et al.
The Journal of Prevention of Alzheimer'S Disease
|
April 19, 2025
Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force
D Angioni, L Middleton, R Bateman, et al.
The Journal of Prevention of Alzheimer'S Disease
|
September 29, 2021
Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force
J Kaye, P Aisen, R Amariglio, et al.
The Journal of Prevention of Alzheimer'S Disease
|
May 8, 2019
Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force
S Gauthier, J Alam, H Fillit, et al.
The Journal of Prevention of Alzheimer'S Disease
|
December 21, 2018
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
D A Messner, P Rabins, A C Downing, et al.
The Journal of Prevention of Alzheimer'S Disease
|
June 25, 2023
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
D Angioni, O Hansson, R J Bateman, et al.
Page
of 8